Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
Recruiting · NCT05541367 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tongji Hospital
View the official record on ClinicalTrials.gov →What this trial is about
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.
Who can take part
Inclusion criteria
- More than 18 years old
- Patients with pathologically confirmed breast cancer
- Sign the informed consent form
Exclusion criteria
- Pregnant women
- Severe underlying diseases that cannot cooperate with PET examination
Where it is running
1 location listed.
- TongjiHospital - Wuhan, Hubei, China